Mapping The Dynamics Of Corneal Stem Cell During Aging And After Wounding And Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$548,403.00
Summary
Restoring vision in patients with corneal blindness is our focus. Before this can be achieved we need to understand how corneal stem cells function. For many reasons these studies cannot be performed in man, so we engineered a mouse in which the location, migration, division, differentiation, death of these cells can be followed indefinitely. This information will allow us to improve current therapeutic options and develop new clinical solution for patients with blinding corneal disease.
A Nanosecond Laser Based Surgical Treatment To Prevent Progression To Vision Loss In Early Age-related Macular Degeneration (AMD)
Funder
National Health and Medical Research Council
Funding Amount
$813,481.00
Summary
We aim to conduct a trial of a new nano-laser based treatment for Age-related Macular Degeneration (AMD) which, if successful in slowing progression of AMD, will lead to a dramatic reduction in vision loss in our community. AMD is the leading cause of irreversible vision loss in people 50 years and older in Australia. The successful outcome will postpone vision loss, benefiting many thousands of Australians, and result in substantial healthcare savings.
Gene-environment Interactions In The Aetiology Of Myopia
Funder
National Health and Medical Research Council
Funding Amount
$671,285.00
Summary
The rapid rise in the prevalence of shortsightedness poses a major public health challenge. The Sydney Myopia Study has collected a large database on environmental risk factors, and has documented a major protective effect of children spending more time outdoors. Other studies suggest that myopia has a major genetic component. This study will collect DNA samples from over 4000 participants in the Sydney Myopia Study, and through genome-wide scanning, will look for gene-environment interactions.
Gene Identification For Keratoconus - A Blinding Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$912,880.00
Summary
Keratoconus is a common eye disease where the cornea at the front of the eye progressively becomes thinner and bulges out, resulting in severe visual impairment in young people. This project is investigating the genetic causes of keratoconus in a large collection of Australian patients. We aim to be better able to predict who will develop the disease and treat them earlier, as well as be able to target treatments to the causes of disease.
Translation Of Glaucoma Blindness Genes To Improve Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$856,795.00
Summary
Glaucoma is a common cause of irreversible blindness. It is currently difficult to predict which patients with the earliest signs of glaucoma will develop blinding stages of the disease. This study will investigate how genes and eye measurements can be used to predict the risk of developing severe glaucoma in people with early signs of disease. This will ensure that high risk individuals can access treatment early, while those at low risk can be spared unnecessary treatment and seen less often.
Anti-vascular Endothelial Growth Factor-B As A Biologic For Treating Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$464,295.00
Summary
We plan to show that an engineered antibody fragment against vascular endothelial growth factor-B is an effective therapeutic drug for two eye diseases, corneal neovascularization and age-related macular degeneration. The innovative aspects of this approach are that it may be safer, and have a different spectrum of activity, than existing ophthalmic anti-angiogenic agents. Furthermore, it may be effective for corneal disease when administered as an eye-drop.
Novel Functional Imaging For Age-related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$564,848.00
Summary
Age-related macular degeneration (AMD) is an eye condition which affects the central retina (the macula) resulting in a loss of central vision. The lack of appropriate clinical tests to monitor the progression of AMD at the early stages of disease hampers the discovery of novel interventions aimed at preventing the development of advanced vision-threatening AMD. In this project, we will investigate the use of a quick and non-invasive imaging technique for monitoring AMD progression.
Dissecting The Great Ophthalmic Masquerade: The Global Giant Cell Arteritis Genomics Consortium.
Funder
National Health and Medical Research Council
Funding Amount
$583,269.00
Summary
Giant cell arteritis (GCA) is the most common form of vasculitis in people over 50 years of age. If untreated it can cause catastrophic complications including blindness, though this can be prevented if treated early. Although there is clear evidence for a role of genetic factors in GCA, these have been little studied. We have established an Australian-led International consortium, with clinical, basic science and statistical expertise to thoroughly investigate this devastating disease.
A Randomised, Multi-Centre, Placebo Controlled Trial Of Fenofibrate For Treatment Of Diabetic Macular Oedema With Economic Evaluation (FORTE Study)
Funder
National Health and Medical Research Council
Funding Amount
$1,588,132.00
Summary
Our project aims to test if adding an inexpensive oral medication, fenofibrate, is effective at improving treatment of diabetic macular oedema. We will use a well-designed, adequately powered, multi-centred randomised placebo controlled trial to test if fenofibrate can treat currently untreatable forms of diabetic macular oedema, and if it can be combined with current treatments to improve outcomes and reduce costs and risks to patients.
The Role Of Purines In Age Related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$682,434.00
Summary
Age Related Macular degeneration (AMD) is a leading cause of blindess. In this project we will examine a possible cause for the development and progression of early AMD. In particular we will determine whether signaling of immune cells via receptors called purinergic receptors influences the removal of cellular debris as we age, predisposing people to the disease.